{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-023545","form_type":"8-K","ticker":"VCNX","cik":"0001205922","company_name":"VACCINEX, INC.","filed_at":"2022-01-31T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.606516+00:00","generated_at":"2026-06-27T13:26:10.716026+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vaccinex raises $9.7M in private placement of 8.75M shares at $1.11; January equity total $13.2M","bullets":["Private placement closed Jan 31 with 8,747,744 shares at $1.11/share; gross proceeds ~$9.7M after amendment adding 2.8M shares.","Affiliated investors include CEO Maurice Zauderer ($2M), Chairman Albert Friedberg ($2M), and director Jacob Frieberg.","Additional $3.5M raised via ATM sales earlier in January at weighted avg $1.16/share, bringing month total to ~$13.2M.","Proceeds will fund development of lead drug candidate pepinemab in cancer and neurodegenerative disease.","Registration rights agreement requires filing resale shelf within 75 days; failure triggers liquidated damages."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-023545","json":"https://secwatch.observer/filing/0001193125-22-023545.json","markdown":"https://secwatch.observer/filing/0001193125-22-023545.md","text":"https://secwatch.observer/filing/0001193125-22-023545.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1205922/000119312522023545/0001193125-22-023545-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1205922/000119312522023545/d285729d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T13:26:10.716026+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}